A signal produced inside the body
Enkephalins belong to the endogenous opioid-peptide system. The word endogenous matters: these peptides are synthesized and released by cells as part of normal biological signaling. They interact with opioid receptors, but they are not the same thing as an externally administered opiate or a long-lived receptor agonist. Their location, timing and concentration are shaped by the tissue that releases them.
Because enkephalins are peptides, their behavior is also different from many small molecules. They are assembled from amino acids, released in response to biological activity and then removed quickly. That short lifetime helps keep signaling local and time-limited. It also means that measuring only receptor affinity would miss a major part of the system: production and clearance determine how much endogenous signal is available.
Why the signal disappears quickly
Multiple peptidases participate in enkephalin breakdown. Two commonly studied enzymes are neprilysin, abbreviated NEP, and aminopeptidase N, abbreviated APN. Experimental dual-inhibitor work shows why researchers often examine both enzymes together: blocking one clearance route does not necessarily close the other route. The relevant scientific object is therefore a network, not a single switch.
Preserving a naturally released peptide is not equivalent to producing an unlimited signal. The body must first release the peptide, other clearance pathways remain, and the magnitude of any downstream response depends on exposure, tissue distribution and receptor context. These distinctions are why a mechanism diagram is useful for generating hypotheses but cannot certify a finished-product effect.
Preservation is different from substitution
A direct receptor agonist supplies an external molecule that activates a receptor according to that molecule's own exposure profile. A preservation strategy instead attempts to slow removal of a signal that the body has already produced. The two architectures can involve related receptor biology while differing substantially in chemistry, timing, distribution and the experiments needed to characterize them.
That distinction should be described precisely. Non-opiate does not automatically mean non-pharmacological, effective, non-sedating or safe. Each of those properties requires its own evidence. A useful explanation separates molecular origin, target mechanism, measured exposure, observed response and safety instead of compressing them into one marketing adjective.
How NOVA-4 serializes the question
Within the NOVA-4 research architecture, C1 is the enkephalin-preservation axis. Candidate identity, NEP activity, APN activity, selectivity, exposure and target engagement are represented as separate obligations. The design therefore records what a candidate is intended to do without silently upgrading that intention into a measured outcome.
This object-based approach makes the research replayable. A source supports a mechanistic proposition; an exact candidate carries a defined assay requirement; and a combination carries additional interaction requirements. If a measurement is absent, the corresponding proposition remains a design target. That separation is the foundation of an evidence-linked product program.